Ranibizumab reimbursement and treatment patterns for neovascular age-related macular degeneration in Taiwan – Results from the 12-month, observational RENOWNED study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Ranibizumab reimbursement and treatment patterns for neovascular age-related macular degeneration in Taiwan – Results from the 12-month, observational RENOWNED study

Published:2022-10 Issue:10 Volume:121 Page:2020-2027
ISSN:0929-6646
Container-title:Journal of the Formosan Medical Association
language:en
Short-container-title:Journal of the Formosan Medical Association

Author:

Chen San-Ni,Lai Chi-Chun,Wang Jia-Kang,Choi Hin-Yeung,Kuo Chien-Neng,Tsai Ching-Yao,Wang Hsing-I,Yang Chung-May

Publisher

Elsevier BV

Subject

General Medicine

Reference17 articles.

1. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents;Tomany;Ophthalmology,2004

2. The treatment of wet age-related macular degeneration;Joussen;Dtsch Arztebl Int,2009

3. Prevalence and risk factors for age-related macular degeneration in the elderly Chinese population in south-western Taiwan: the Puzih eye study;Huang;Eye,2014

4. Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan;Chang;Sci Rep,2018

5. Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study;Tano;Acta Ophthalmol,2011

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ranibizumab;Reactions Weekly;2022-11-26

2. Therapeutic Approaches for Age-Related Macular Degeneration;International Journal of Molecular Sciences;2022-10-04

3. Highlights;Journal of the Formosan Medical Association;2022-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP